SCYNEXIS INC
SCYX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001178253
Insider trades, last 90 days
None
- No open-market purchases or sales were filed in the last 90 days.
13F holders, Q2 2026
40
- −4 vs. Q1 2026
- Total value $21.01M
Superinvestors holding SCYX
0
- None of the superinvestors held SCYX at the end of Q2 2026.
Price chart
Latest insider trades
View all: Latest insider tradesOpen-market purchases and sales by SCYX insiders, newest first.
| Filed (ET) | Trade date | Insider | Transaction | Shares | Avg price | Value | Shares after | Holding change | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Apr 2, 2026 | Apr 1, 2026 | Angulo Gonzalez DavidChief Executive Officer | PPurchaseCommon Stock | +108.7K | – | – | 1.36M | +8.7% | SEC |
| Apr 2, 2026 | Apr 1, 2026 | Angulo Gonzalez DavidChief Executive Officer | PPurchaseCommon Stock · Derivative | +108.7K | – | – | 108.7K | – | SEC |
| Sep 16, 2024 | Sep 12, 2024 | Angulo Gonzalez DavidChief Executive Officer | PPurchaseCommon Stock | +20K | $1.37 | +$27.4K | 507.87K | +4.1% | SEC |
| Apr 28, 2022 | Apr 26, 2022 | Taglietti MarcoChief Executive Officer | PPurchaseCommon Stock | +75K | $3.00 | +$225K | 272.07K | +38.1% | SEC |
| Apr 28, 2022 | Apr 26, 2022 | Sukenick ScottGeneral Counsel | PPurchaseCommon Stock | +3.5K | $3.00 | +$10.5K | 53.5K | +7.0% | SEC |
Top 5 13F holders, Q2 2026
View all: Top 5 13F holders, Q2 2026The largest institutional positions in SCYX at the end of Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| GREAT POINT PARTNERS LLC | 944,292 | $3.84M | 0.91% | −6,610,055−87.5% | Reduced |
| Squadron Capital Management LLC | 756,884 | $3.08M | 1.05% | −6,851,811−90.1% | Reduced |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 543,478 | $2.21M | 0.00% | +543,478 | New |
| Propel Bio Management, LLC | 543,478 | $2.21M | 1.16% | +543,478 | New |
| Woodline Partners LP | 387,520 | $1.58M | 0.00% | +387,520 | New |